HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Benichou N, Guillevin L, Charles P, et al.

Prognostic Value of Persistent Proteinuria and Hematuria After Induction Therapy in ANCA-Associated Vasculitides

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:53A 2020


In ANCA-associated vasculitides (AAV), hematuria and proteinuria are biomarkers reflecting renal involvement at diagnosis. Yet, the prognostic value of their persistence after immunosuppressive induction therapy, which may reflect renal damage or persistent disease, remains uncertain.


This is a post hoc study including participants of 5 European randomized clinical trials on AAV (MAINRITSAN, MAINRITSAN2, RITUXVAS, MYCYC, IMPROVE).
We examined the association of PCR (urine protein-creatinine ratio) and hematuria on spot urine samples collected at the end of induction therapy with the occurrence of i) a combined endpoint of death and/or end stage renal disease (ESRD), and ii) relapse during follow-up.


Among 571 patients (59% men, median age 60 years), 60% had PR3-ANCA, 35% had MPO-ANCA, 77% had renal involvement. After induction therapy, 157/526 (29.8%) had persistent hematuria, 165/481 (34.3%) had PCR ≥ 0.05 g/mmol. After a median follow up of 28 months (IQR : 18-42), and adjustment for sex, age, ANCA serotype, initial eGFR, persistent hematuria, a PCR ≥ 0.05 g/mmol after induction was associated with risk of death and/or ESRD (adjusted Hazard Ratio (HR) = 4.08, 95% confidence interval (CI95) 1.48-11.25, p = 0.006). Persistent hematuria was associated with renal relapse (adjusted subdistribution HR = 2.18, CI95 1.14-4.18, p = 0.019) but not with any relapse (adjusted sHR = 1.10, CI95 0.78-1.56, p = 0.59) nor with death and/or ESRD (adjusted HR = 1.88, CI95 = 0.83-4.29, p = 0.132).


In this large cohort of AAV patients, persistent proteinuria after induction therapy was an independent predictor of death and/or ESRD, whereas persistent hematuria after induction therapy was an independent predictor of renal relapse. These parameters must be taken into account to assess long-term renal prognosis of AAV patients.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.